Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status approved; investigational
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 0781-3430; 11014-0094; 66302-350; 66302-648; 66302-748; 66302-361; 66302-363; 66302-620; 66302-720; 0703-0676; 43598-646; 43598-647; 66302-302; 66302-325; 66302-616; 66302-362; 0703-0666; 14501-0015; 42023-209; 62332-515; 66302-110; 66302-300; 66302-610; 54893-0024; 43598-649; 62332-514; 62332-517; 66302-102; 66302-206; 66302-732; 58159-041; 68245-0008; 43598-648; 66302-120; 66302-600; 66302-650; 66302-764; 0703-0686; 0781-3420; 0781-3425; 81861-0029; 66302-101; 66302-310; 66302-630; 66302-664; 0781-3427; 42023-206; 66302-105; 66302-640; 42023-207; 62332-516; 66302-632; 66302-716; 42023-208
UNII RUM6K67ESG
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchitis22.07.01.001; 11.01.09.001--
Bundle branch block right02.03.01.0110.000082%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cardiac arrest02.03.04.0010.001892%
Cardiac failure02.05.01.0010.003701%
Cardiac failure acute02.05.01.0050.000082%Not Available
Cardiac failure congestive02.05.01.0020.002508%Not Available
Cardiac failure high output02.05.01.0100.000123%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000699%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000740%Not Available
Cardiomegaly02.04.02.0010.000304%Not Available
Catheter site related reaction12.07.02.001; 08.02.02.0010.000082%Not Available
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.008002%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.011539%Not Available
Chills15.05.03.016; 08.01.09.0010.002459%
Cholecystitis09.03.01.0010.000288%
Cholecystitis acute09.03.01.0030.000082%Not Available
Cholelithiasis09.03.01.0020.000345%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.001563%Not Available
Circulatory collapse24.06.02.0010.000247%Not Available
Cold sweat08.01.03.024; 23.02.03.0020.000164%Not Available
Condition aggravated08.01.03.0040.006728%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Cor pulmonale24.08.03.001; 22.06.01.003; 02.05.03.0010.000247%Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.006; 12.02.01.0360.000082%Not Available
Cough22.02.03.0010.027075%
Cyanosis02.11.04.004; 24.03.01.007; 22.02.02.007; 23.06.04.0050.000510%
Death08.04.01.0010.027346%
Decreased activity19.11.01.002; 08.01.01.0060.000263%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene